NEJM expert review covers statins in the elderly, IgG4-related disease, ER+ breast cancer and weekly oral HIV regimen

NEJM Group's expert review highlights four studies: 9,971 Australians aged 70 or older without cardiovascular disease, diabetes or dementia randomized to atorvastatin 40 mg daily or placebo found starting statins beneficial and safe; phase III obexelimab lowered relapse risk and corticosteroid exposure in IgG4-related disease at 52 weeks; giredestrant plus everolimus improved outcomes after CDK4/6 inhibitor progression in ER+/HER2- advanced breast cancer; and weekly oral islatravir plus lenacapavir maintained viral suppression after switching from daily B/F/TAF. Europe's first Joint Clinical Assessment under the HTA regulation places comparative effectiveness at the centre of drug evaluation.